A scientist has just registered copyright for a cold vaccine

Austrian scientist Rudolf Valenta has filed a patent for the cold vaccine and says it can be marketed within 10 years. Copyright registration applications have been sent to the European Patent Registration Authority, which indicates more than 200 scientific papers that underlie this technology.

Valenta has been studying measures to prevent cold and allergy symptoms for decades. He said he had touched something important and confident about how to prevent rhinovirus from causing colds in people.

The cold is extremely uncomfortable.

According to his explanation on The Independent, this technique is practically not groundbreaking, but is based on a long-standing principle of making the immune system self-control in response to a virus. It is important to change how the immune system is affected by rhinovirus infection - a major cause of colds.

Instead of allowing the immune system to try on its own, and often failing to penetrate the virus's core as usual, the vaccine redirects the immune response to the outer shell of the virus. Valenta says this solves the biggest challenges in treating or preventing the spread of colds. Because rhinovirus is so diverse with 99 known strains in humans, it has a high mutation ability.

"We took the rhinovirus shells, just important parts, and attached them to a carrier protein. It is a very classic principle, to regulate the reaction to the antibody. Diversity (of strains) rhinovirus is not serious by identifying key points on the virus, " Valenta said.

The virus is very easy to change to get rid of the immune system.

The vaccine was developed based on a study conducted at Vienna General Hospital in 2012, where Valenta and colleagues studied 59 young patients and their reactions to rhinovirus. One of the key findings is that the body's immune system tries to neutralize the virus by attaching antibodies to the exposed part of the virus, after its outer shell is removed. The area where the antibody binds is called epitope , and the researchers found that the epitopes were ineffective. Meanwhile, the virus can quickly change and escape the immune defense mechanism in humans.

Based on the results, researchers can design vaccines that can divert antibody responses to effective sites for treating rhinovirus-related diseases, such as colds, asthma and disease. Chronic obstructive pulmonary (COPD)."With the first proteins we built, we had a very good inhibition. We believe we have a favorable route with what we do," Valenta said.

Jonathan Ball, professor of molecular viruses at Nottingham University (UK), who is not involved in the study, said the team "could do something" , but there were many challenges on the side. before, and it is too early to be happy.